WINNIPEG,  April 30, 2025 — TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that, taking steps to enter the European poultry market, the Company is pursuing the data required for approval of its flagship AviPhage product through a European-based broiler chicken pilot study. The successful completion of this trial will provide data to support an application for European Medicines Agency (EMA) product approval.

AviPhage is a bacteriophage-based poultry solution that has been shown to promote gut health, increase bird weight, improve feed conversion ratio, decrease signs of disease, and reduce mortality.

Highlights

• The trial will be conducted on broiler chickens for 35 days with trial data expected to be available within 60 days. The trial will measure key performance indicators that prove product efficacy such as mortality, feed conversion rate, weight gain, and signs of disease. 

• A successful trial will demonstrate that the study group that was given AviPhage performs better than the control group that did not receive AviPhage, particularly with respect to increased weight, improved feed conversion ratio and decreased mortality. 

• Subsequently, Cytophage plans to conduct a larger study in a European commercial barn to further demonstrate the utility and efficacy of AviPhage in real-world conditions.  

• The data accumulated from these studies will support Cytophage’s objectives to enter into the European Union (EU) market. 

All EU member countries have banned the use of antibiotics for disease prevention and as growth promoters, and poultry producers are evaluating antibiotic alternatives that will manage bacteria in poultry.

Cytophage plans to use this trial data for its regulatory submission for product approval to the EMA. The EU is one of the largest poultry producers globally with a total production of over 6 billion broiler chickens each year representing a highly desirable market with substantial commercial potential for Cytophage.

Cytophage CEO Dr. Steven Theriault commented: “We continue to strategically collect data required for our product approval in the EU.  We have every confidence that AviPhage will prove to be a product that farmers will want to use in their barns to improve and maintain the health of their flocks. Fewer mortalities and healthier birds positively impact the bottom line for poultry producers.”

The Company also wishes to announce that it has filed its financial results for the year ended 31 December 2024. The audited consolidated financial statements should be read in conjunction with the accompanying Management’s Discussion and Analysis for the year ended 31 December 2024. All documents are available on sedarplus.com on the Company's profile page.

About Cytophage 
Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. 

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature’s version of antibiotics. 

Cytophage is improving bacteria’s natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products. 

Cytophage is using a de-risked and patented technology to advance innovative and cost competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.  

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

For further information please contact:  

Heather Medwick, Chief Operating Officer 
heather@cytophage.com | 431 388 8873 

Cytophage Investor Alerts: https://cytophage.com/subscribe/

 

Cautionary Statement on Forward-Looking Information 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.